Clinical trials: Ritonavir
HIV Infection
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy.
- Trial name
- NCT00114933
- Testing
- Stopping nucleosides and continuing lopinavir/ritonavir monotherapy
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Arribas, Jose R., M.D.
HIV Infection
Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject
This is an open label randomized clinial trial to evaluate the treatment with darunavir/ritonavir (800mg/100mg) plus lamivudine (300 mg) once daily versus continuing with darunavir/ritonavir (800mg/100mg) once daily plus…
- Trial name
- DUAL (NCT02159599)
- Testing
- Darunavir/Ritonavir, Lamivudine, Emtricitabine/tenofovir or abacavir/lamivudine
- Where
- 21 sites in Spain
- Volunteers
- 249 people
- Sponsor
- Fundacion SEIMC-GESIDA
HIV Infections
Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents
The purpose of this study was to find a safe and tolerable dose of the protease inhibitor (PI) atazanavir (ATV), with or without a low-dose boost of the PI ritonavir (RTV), when taken with other anti-HIV drugs in HIV infected…
- Trial name
- NCT00006604
- Testing
- ATV, Ritonavir
- Where
- 36 sites in United States, Puerto Rico and 1 more
- Volunteers
- 195 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer
Healthy
Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers
Study to characterize the effects of two dose combinations of Tipranavir (TPV)/Ritonavir (RTV) (TPV 750 mg/RTV 200 mg and TPV 500 mg/RTV 100 mg), administered twice-daily, on the pharmacokinetics of Norethindrone-Ethinyl…
- Trial name
- NCT02245438
- Testing
- Tipranavir low dose, Tipranavir high dose, Ritonavir low dose
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
Kaletra and Viread in Antiretroviral Naïve Patients
Once daily antiretroviral therapy with Viread (tenofovir DF, 300mg) plus Kaletra (LPV/r, 800mg/200mg) will be effective in suppressing and maintaining suppression of HIV RNA to <50 copies/ml in antiretroviral naïve patients…
- Trial name
- NCT00679926
- Testing
- Once daily
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Oklahoma State University Center for Health Sciences
COVID-19
Umifenovir in Hospitalized COVID-19 Patients
The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical…
- Trial name
- UAIIC (NCT04350684)
- Testing
- Umifenovir, Interferon-β 1a, Lopinavir / Ritonavir
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Chronic Hepatitis c
Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients
To evaluate efficacy and safety of Ombitasvir, paritaprevir, and ritonavir plus ribavirin based therapy for chronic hepatitis C with or without compensated cirrhosis in haemodialysis patients.
- Trial name
- NCT03067883
- Testing
- Ombitasvir, Paritaprevir and Ritonavir
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Ain Shams University
HIV Infection
Switch to Darunavir/r + Maraviroc Quaque Die in Patients With R5 Tropism by Viral DNA Genotyping (GUSTA)
Objectives of the study: 1. To verify the safety and the efficacy of the study treatment, defined as the persistent control of the virus' replication at 48 weeks after the simplification to maraviroc + darunavir with ritonavir in…
- Trial name
- GUSTA (NCT01367210)
- Testing
- Maraviroc, Darunavir/r, current antiretroviral therapy with 3 drugs
- Where
- Italy
- Volunteers
- 165 people
- Sponsor
- Catholic University of the Sacred Heart
HIV Infections
ABT-378/Ritonavir and Efavirenz in HIV-Infected Patients Who Have Taken More Than One Protease Inhibitor in the Past
The purpose of this study is to see if ABT-378/ritonavir plus efavirenz is safe and effective in lowering the amount of HIV in the blood of patients who have been treated with more than 1 protease inhibitor (PI).
- Trial name
- NCT00004582
- Testing
- Lopinavir/Ritonavir, Efavirenz
- Where
- United States
- Sponsor
- ViRx
HIV
Clinical Study of an Aluvia-based HAART Regimen for Prevention of Mother-to-child HIV Transmission in Africa
Therapeutic options to prevent vertical transmission of HIV remain limited. Combination antiretroviral therapy in the form of HAART (Highly Active Anti Retroviral Therapy) is generally recommended in the developed world, both for…
- Trial name
- NCT01088516
- Testing
- Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC
- Where
- Zambia
- Volunteers
- 280 people
- Sponsor
- University of Zambia
HIV Infections
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy.
- Trial name
- NCT00619944
- Testing
- Lumefantrine - lopinavir/ritonavir drug interaction, Lumefantrine only arm
- Where
- Uganda
- Volunteers
- 32 people
- Sponsor
- Makerere University
Human Immunodeficiency Virus
Nucleosides And Darunavir/Dolutegravir In Africa
This trial evaluates options for second-line antiretroviral therapy in patients failing on a non-nucleoside reverse transcriptase inhibitor (NNRTI) and tenofovir (TDF)-based first-line regimen in the setting of the public health…
- Trial name
- NADIA (NCT03988452)
- Testing
- Darunavir, Ritonavir, Dolutegravir
- Where
- Uganda
- Volunteers
- 465 people
- Sponsor
- Makerere University
Tuberculosis
Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
Tuberculosis (TB) is a global public health concern and developing new treatment regimens is an important research priority. PA-824 is an experimental TB medication.
- Trial name
- NCT01571414
- Testing
- PA-824, Efavirenz (EFV), Lopinavir/Ritonavir (LPV/r)
- Where
- 4 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Hepatitis C Virus (HCV)
ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-Administered With Ribavirin (RBV) in Treatment Naïve and Treatment Experienced Asian Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Compensated Cirrhosis
This is a Phase 3, open-label, multicenter study evaluating the efficacy and safety of ABT-450/r/ ABT-267 and ABT-333 coadministered with RBV for 12 weeks in HCV genotype 1b, treatment naïve and Interferon (IFN) (alpha, beta or…
- Trial name
- NCT02517528
- Testing
- ABT-450/r/ABT-267, ABT-333, ribavirin
- Volunteers
- 104 people
- Sponsor
- AbbVie
HIV-infected Children
Pediatric Study for Appropriate Dose of Ritonavir Boosted Lopinavir in Thai HIV-infected Children (PEARL)
To compare the safety and efficacy of low-dose versus standard dose lopinavir/ritonavir containing HAART regimen in virological suppress, HIV RNA viral load < 50 copies/ml at 48 week
- Trial name
- NCT01307124
- Testing
- kaletra
- Where
- 10 sites in Thailand
- Volunteers
- 199 people
- Sponsor
- The HIV Netherlands Australia Thailand Research Collaboration
Infection, Human Immunodeficiency Virus I, HIV-1 Infection
A Dose Ranging Study Of GW640385 Boosted With Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults
This is a two phase study (randomised and non-randomised phase). The randomised phase will initially examine 4 blinded doses of GW640385 boosted with rtv (with continuation of current background therapy) in comparison to an…
- Trial name
- NCT00242879
- Testing
- Physician determined comparator PI + ritonavir, GW640385 + ritonavir
- Where
- 70 sites in United States, Australia and 9 more
- Volunteers
- 130 people
- Sponsor
- ViiV Healthcare
Pregnancy, HIV
The Effect of Pregnancy on the Pharmacokinetics of the Kaletra Tablet
In this study, we are looking at blood concentrations of Kaletra in HIV positive patients during pregnancy. The patients will come in for 4 visits lasting ~24hrs.
- Trial name
- NCT00766818
- Testing
- Kaletra
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of North Carolina, Chapel Hill
COVID-19
The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.
The ECLA PHRI COLCOVID Trial is a simple, pragmatic randomized open controlled trial to test the effects of colchicine on moderate/high-risk hospitalized COVID-19 patients with the aim of reducing mortality and/or new requirement…
- Trial name
- COLCOVID (NCT04328480)
- Testing
- Colchicine, Local standard of care
- Where
- Argentina
- Volunteers
- 1,279 people
- Sponsor
- Estudios Clínicos Latino América
COVID-19, Hospitalized COVID-19 Patients
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
This study aims first to assess the efficacy, safety, and effectiveness of the LUSZ COVID-19 therapy consisting of a comparative study of three different treatment approaches: antiviral, antiretroviral, and immunosuppressive IL-6…
- Trial name
- LUSZ_AVIST (NCT05925140)
- Testing
- Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab
- Where
- 2 sites in Lebanon
- Volunteers
- 1,000 people
- Sponsor
- Lebanese University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.